Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vincent Cottin. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019

Member's Comments

No comment yet.

Related content which might interest you: Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Clinical management of the idiopathic interstitial pneumonias: an example of an integrated approach to interstitial lung diseases Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias Year: 2006 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Variation in mortality from interstitial lung disease by diagnosis Source: International Congress 2015 – IIPs: orphan Year: 2015 Comparison of registries of interstitial lung diseases in three European countries Source: Eur Respir J 2001; 18: 114S-118S Year: 2001 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Rare interstitial lung diseases Source: School Course 2014 - Interstitial lung diseases Year: 2014 Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Source: Eur Respir J 2011; 38: 384-391 Year: 2011 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016